Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Colt Williams"'
Autor:
Colt Williams, MD, Leigh Meyer, BA, Omar Kawam, BS, Konstantinos Leventakos, MD, PhD, Erin S. DeMartino, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 7, Iss 6, Pp 524-533 (2023)
Objective: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. Patients and Methods: We conducted structured interviews with cancer patients participating in phase I clinical trials. Usi
Externí odkaz:
https://doaj.org/article/ac20aecb190a45efac1589593b561a2f
Autor:
Colt Williams
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8381cf8b82ad03087cf0795a17476904
https://pubmed.ncbi.nlm.nih.gov/35119907
https://pubmed.ncbi.nlm.nih.gov/35119907
Autor:
Colt Williams, Sherry Chesak, Deirdre R. Pachman, Laura Rhee, Ross Dierkhising, Konstantinos Leventakos
Publikováno v:
Journal of Clinical Oncology. 40:11016-11016
11016 Background: Stress Management and Resiliency Training (SMART) is a validated resilience training program designed to reduce stress, improve emotional resilience, and decrease burnout. The prevalence of burnout among practicing oncologists is as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83465f59fecdc500a566afff2925aeb3
https://doi.org/10.1200/jco.2022.40.16_suppl.11016
https://doi.org/10.1200/jco.2022.40.16_suppl.11016
Autor:
Aakash Desai, Caleb Scheckel, Chelsee J. Jensen, Jacob Orme, Colt Williams, Nilay Shah, Konstantinos Leventakos, Alex A. Adjei
Publikováno v:
JAMA Network Open
This cross-sectional study examines trends in costs of brand-name medications for treatment of non–small cell lung cancer and within-class price differences between these medications in the US from 2015 to 2020.
Key Points Question How did the
Key Points Question How did the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d74d06ff18a3a203744aeb64327764
https://doi.org/10.1001/jamanetworkopen.2021.44923
https://doi.org/10.1001/jamanetworkopen.2021.44923
Autor:
Roger N. Pearse, Peter A. Forsberg, Colt Williams, Daniel W. Sherbenou, Leora Boussi, Scott Ely, Tomer M Mark, Linda Tegnestam, Morton Coleman, Arthur Perry, Adriana C Rossi, John N. Allan, Ruben Niesvizky, Angelique Boyer, David Jayabalan, Karen Pekle
Publikováno v:
American journal of hematology. 94(5)
Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase 2 study of 72 patients with NDMM to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c57ccdd4e9946dda604f62819348bf22
https://pubmed.ncbi.nlm.nih.gov/30740766
https://pubmed.ncbi.nlm.nih.gov/30740766